Drug Trial Radar · NCT06600581
Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness
Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Dec 19, 2024
Primary completion
Jul 15, 2026
Study completion Dec 15, 2026
Sponsor
- Lead sponsor
- Immunis, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Placebo controlled study for safety and efficacy of IMM01-STEM on muscle performance in seniors with obesity and muscle weakness
Conditions
- Muscle Performance
- Sarcopenic Obesity
Interventions
IMM01-STEMBiological
IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling. This intervention is given 2mL twice a week.
PlaceboOther
Saline. This intervention is given 2mL twice a week.
IMM01-STEM alternating with placebo (saline)Biological
This intervention consists of IMM01-STEM given once a week and placebo given one a week. IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Time Frame: Day 0 to Day 28
- Change over time in gait speedTime frame: Time Frame: Day 0 to Day 171
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
National Institute of Clinical Research (NICR)
Garden Grove, California
National Institute of Clinical Research (NICR)
Pomona, California
Johnson Country Clinical Trials (JCCT)
Lenexa, Kansas
Tekton Research
Wichita, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.